572632-M
SU5614
A potent, cell-permeable, reversible, ATP-competitive, and selective inhibitor of VEGF (Flk-1; IC50 = 1.2 µM) and PDGF (IC50 = 2.9 µM) receptor tyrosine kinases.
别名:
SU5614, 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone, VEGFR Tyrosine Kinase Inhibitor VII, VEGFR2 Kinase Inhibitor IX
登录 查看组织和合同定价。
选择尺寸
关于此项目
Assay:
≥95% (HPLC)
Form:
solid
Storage condition:
OK to freeze, protect from light
InChI key
XLBQNZICMYZIQT-UHFFFAOYSA-N
InChI
1S/C15H13ClN2O/c1-8-5-9(2)17-14(8)7-12-11-6-10(16)3-4-13(11)18-15(12)19/h3-7,17H,1-2H3,(H,18,19)
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
orange-red
solubility
DMSO: 10 mg/mL
storage temp.
2-8°C
General description
A potent, cell-permeable, reversible, ATP-competitive, and selective inhibitor of VEGF (Flk-1; IC50 = 1.2 µM) and PDGF (IC50 = 2.9 µM) receptor tyrosine kinases. Does not have any effect on the EGF and IGF receptor tyrosine kinases. Also inhibits the VEGF-driven mitogenesis of human umbilical vein endothelial cells (HUVECs; IC50 ≤ 680 nM). Inhibits Flt3 phosphorylation in Flt3/Itd-BaF3 cells.
Biochem/physiol Actions
Primary Target
VEGF Flk-1
VEGF Flk-1
Target IC50: 1.2 µM, 2.9 µM against VEGF (Flk-1) and PDGF receptor tyrosine kinases, respectively; ≤680 nM against the VEGF-driven mitogenesis of human umbilical vein endothelial cells (HUVECs)
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
Other Notes
Cools, J., et al. 2004. Cancer Res.64, 6385.
Sun, L., et al. 1998. J. Med. Chem. 41, 2588.
Sun, L., et al. 1998. J. Med. Chem. 41, 2588.
Legal Information
Not available for sale in the United States.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持